Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes

Iris M. de Lange*, Boudewijn Gunning, Anja C. M. Sonsma, Lisette van Gemert, Marjan van Kempen, Nienke E. Verbeek, Joost Nicolai, Nine V. A. M. Knoers, Bobby P. C. Koeleman, Eva H. Brilstra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1154-1165
Number of pages12
JournalEpilepsia
Volume59
Issue number6
DOIs
Publication statusPublished - Jun 2018

Keywords

  • cognition
  • Dravet syndrome
  • GEFS
  • SCN1A
  • sodium-channel blockers
  • SEVERE MYOCLONIC EPILEPSY
  • LONG-TERM COURSE
  • SCN1A MUTATIONS
  • FEBRILE SEIZURES
  • SODIUM-CHANNEL
  • INFANCY
  • DIAGNOSIS
  • VARIANTS
  • GENE
  • ENCEPHALOPATHY

Cite this

de Lange, I. M., Gunning, B., Sonsma, A. C. M., van Gemert, L., van Kempen, M., Verbeek, N. E., Nicolai, J., Knoers, N. V. A. M., Koeleman, B. P. C., & Brilstra, E. H. (2018). Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia, 59(6), 1154-1165. https://doi.org/10.1111/epi.14191